ReNeuron Group Plc (RENE) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by the publisher to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
Dec 08, 2022: ReNeuron presents new data highlighting the advantages of its novel type of iPSCs including data from the Company's collaboration with University College London
Dec 02, 2022: ReNeuron : Interim Results for the six months ended 30 September 2022
Oct 07, 2022: Positive exosome data presented at US Conference
The profile contains critical company information including:
- Business description - A detailed description of the company’s operations and business divisions.
- Corporate strategy - Analyst’s summarization of the company’s business strategy.
- SWOT Analysis - A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history - Progression of key events associated with the company.
- Major products and services - A list of major products, services and brands of the company.
- Key competitors - A list of key competitors to the company.
- Key employees - A list of the key executives of the company.
- Executive biographies - A brief summary of the executives’ employment history.
- Key operational heads - A list of personnel heading key departments/functions.
- Important locations and subsidiaries - A list and contact details of key locations and subsidiaries of the company.
- Detailed financial ratios for the past five years - The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods - The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Highlights
ReNeuron Group Plc (ReNeuron) is a stem cell company that develops innovative stem cell therapies targeting areas of significant unmet medical need. ReNeuron’s therapeutic candidates in clinical development are focused at treating patients left disabled by a stroke and the blindness-causing disease, retinitis pigmentosa, oncology, diabetes and neurodegenerative diseases. The company utilizes exclusive stem cell technologies to develop cell-based therapies for significant disease conditions where the cells can be administered off-the-shelf to any fit patient without the requirement for additional immunosuppressive drug treatments. ReNeuron’s technology platforms include hRPC platform, CTX platform and Exosomes platform. ReNeuron is headquartered in Pencoed, Bridgend, the UK.ReNeuron Group Plc Key Recent Developments
Jan 03, 2023: ReNeuron Group : Directorate changeDec 08, 2022: ReNeuron presents new data highlighting the advantages of its novel type of iPSCs including data from the Company's collaboration with University College London
Dec 02, 2022: ReNeuron : Interim Results for the six months ended 30 September 2022
Oct 07, 2022: Positive exosome data presented at US Conference
Key benefits of buying this profile include:
You get detailed information about the company and its operations to identify potential customers and suppliers.- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Table of Contents
Section 1 - About the Company- ReNeuron Group Plc - Key Facts
- ReNeuron Group Plc - Key Employees
- ReNeuron Group Plc - Key Employee Biographies
- ReNeuron Group Plc - Major Products and Services
- ReNeuron Group Plc - History
- ReNeuron Group Plc - Company Statement
- ReNeuron Group Plc - Locations And Subsidiaries
- Head Office
- Other Locations & Subsidiaries
- Company Overview
- ReNeuron Group Plc - Business Description
- ReNeuron Group Plc - Corporate Strategy
- ReNeuron Group Plc - SWOT Analysis
- SWOT Analysis - Overview
- ReNeuron Group Plc - Strengths
- ReNeuron Group Plc - Weaknesses
- ReNeuron Group Plc - Opportunities
- ReNeuron Group Plc - Threats
- ReNeuron Group Plc - Key Competitors
- Financial Ratios - Annual Ratios
- Performance Chart
- Financial Performance
- Financial Ratios - Interim Ratios
- Financial Ratios - Ratio Charts
- ReNeuron Group Plc, Pharmaceuticals & Healthcare, Deals By Year, 2017 to YTD 2023
- ReNeuron Group Plc, Pharmaceuticals & Healthcare, Deals By Type, 2017 to YTD 2023
- ReNeuron Group Plc, Recent Deals Summary
- Jan 03, 2023: ReNeuron Group : Directorate change
- Dec 08, 2022: ReNeuron presents new data highlighting the advantages of its novel type of iPSCs including data from the Company's collaboration with University College London
- Dec 02, 2022: ReNeuron : Interim Results for the six months ended 30 September 2022
- Oct 07, 2022: Positive exosome data presented at US Conference
- Sep 14, 2022: ReNeuron Group Announces Appointment of Chief Financial Officer and Chief Business Officer
- Aug 15, 2022: ReNeuron Group Notice of AGM
- Aug 01, 2022: ReNeuron Group Announce Directorate Change
- Jul 04, 2022: ReNeuron Group Preliminary Results for the year ended 31 March 2022
- May 03, 2022: ReNeuron to present at International Society of Cell and Gene Therapy
- Mar 22, 2022: ReNeuron Group announces Directorate Changes
- Methodology
- Ratio Definitions
- About the Publisher
- Contact the Publisher
- Disclaimer
- ReNeuron Group Plc, Key Facts
- ReNeuron Group Plc, Key Employees
- ReNeuron Group Plc, Key Employee Biographies
- ReNeuron Group Plc, Major Products and Services
- ReNeuron Group Plc, History
- ReNeuron Group Plc, Subsidiaries
- ReNeuron Group Plc, Key Competitors
- ReNeuron Group Plc, Annual Ratios
- ReNeuron Group Plc, Interim Ratios
- ReNeuron Group Plc, Pharmaceuticals & Healthcare, Deals By Year, 2017 to YTD 2023
- ReNeuron Group Plc, Pharmaceuticals & Healthcare, Deals By Type, 2017 to YTD 2023
- ReNeuron Group Plc, Recent Deals Summary
- Currency Codes
- Capital Market Ratios
- Equity Ratios
- Profitability Ratios
- Cost Ratios
- Liquidity Ratios
- Leverage Ratios
- Efficiency Ratios
- ReNeuron Group Plc, Performance Chart (2018 - 2022)
- ReNeuron Group Plc, Ratio Charts
- ReNeuron Group Plc, Pharmaceuticals & Healthcare, Deals By Year, 2017 to YTD 2023
- ReNeuron Group Plc, Pharmaceuticals & Healthcare, Deals by Type, 2017 to YTD 2023
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- ViaCord LLC
- Geron Corp
- CovalAb UK Ltd
- Avita Medical Inc
- Tissue Regenix Group PLC
- Biostatus Ltd
- CBR Systems Inc
